ADMA Biologics, Inc. (ADMA) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $10.47 (+2.20%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 13, 2026 | Anthony Petrone | Mizuho Securities | $24.00 | +129.1% |
| Oct 14, 2024 | Raghuram Selvaraju | H.C. Wainwright | $18.00 | +71.8% |
| Jun 20, 2024 | Anthony Petrone | Mizuho Securities | $14.00 | +33.7% |
Top Analysts Covering ADMA
ADMA vs Sector & Market
| Metric | ADMA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.24 | 2.41 |
| Analyst Count | 2 | 8 | 18 |
| Target Upside | +114.8% | +1150.1% | +14.9% |
| P/E Ratio | 17.46 | 6.85 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $148M | $149M | $151M | 3 |
| 2026-09-30 | $158M | $159M | $161M | 1 |
| 2026-12-31 | $173M | $175M | $177M | 2 |
| 2027-03-31 | $172M | $174M | $176M | 1 |
| 2027-06-30 | $182M | $184M | $186M | 2 |
| 2027-09-30 | $197M | $199M | $200M | 2 |
| 2027-12-31 | $217M | $219M | $222M | 1 |
| 2028-12-31 | $930M | $930M | $930M | 3 |
| 2029-12-31 | $1.10B | $1.11B | $1.12B | 2 |
| 2030-12-31 | $1.21B | $1.22B | $1.23B | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.22 | $0.22 | $0.22 | 1 |
| 2026-09-30 | $0.25 | $0.25 | $0.25 | 1 |
| 2026-12-31 | $0.28 | $0.29 | $0.29 | 1 |
| 2027-03-31 | $0.24 | $0.24 | $0.24 | 1 |
| 2027-06-30 | $0.27 | $0.27 | $0.27 | 1 |
| 2027-09-30 | $0.30 | $0.30 | $0.30 | 1 |
| 2027-12-31 | $0.36 | $0.36 | $0.36 | 1 |
| 2028-12-31 | $1.52 | $1.65 | $1.74 | 3 |
| 2029-12-31 | $2.04 | $2.05 | $2.07 | 1 |
| 2030-12-31 | $2.31 | $2.33 | $2.35 | 1 |
Frequently Asked Questions
What is the analyst consensus for ADMA?
The consensus among 2 analysts covering ADMA Biologics, Inc. (ADMA) is Buy with an average price target of $22.50.
What is the highest price target for ADMA?
The highest price target for ADMA is $24.00, set by Anthony Petrone at Mizuho Securities on 2026-04-13.
What is the lowest price target for ADMA?
The lowest price target for ADMA is $14.00, set by Anthony Petrone at Mizuho Securities on 2024-06-20.
How many analysts cover ADMA?
2 analysts have issued ratings for ADMA Biologics, Inc. in the past 12 months.
Is ADMA a buy or sell right now?
Based on 2 analyst ratings, ADMA has a consensus rating of Buy (2.50/5) with a +114.8% upside to the consensus target of $22.50.
What are the earnings estimates for ADMA?
Analysts estimate ADMA will report EPS of $0.22 for the period ending 2026-06-30, with revenue estimated at $149M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.